# Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab

> **NCT03056092** · PHASE4 · UNKNOWN · sponsor: **Unity Health Toronto** · enrollment: 168 (estimated)

## Conditions studied

- Age Related Macular Degeneration
- Diabetic Macular Edema
- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Intravitreal ranibizumab

## Key facts

- **NCT ID:** NCT03056092
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-28
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056092, "Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03056092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*